Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TransMedics Group, Inc. (TMDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. TransMedics is a medical technology company focused on organ transplant therapy, and its filings give detailed insight into how it reports financial performance, manages risks, and documents material events related to its Organ Care System (OCS) and National OCS Program (NOP).
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand revenue from OCS products and NOP services, operating expenses, and discussions of risk factors such as dependence on the OCS platform, regulatory approvals, logistics capabilities, indebtedness, and healthcare policy changes. Form 8-K current reports capture material events, including quarterly financial results, aircraft acquisitions for the NOP fleet, and other significant corporate developments.
TransMedics’ filings also discuss the acquisition and use of fixed-wing aircraft for transporting donor organs, its collaboration and logistics strategy, and the regulatory environment for both its medical devices and aviation transportation services. Disclosures highlight the importance of maintaining FDA and other regulatory approvals for OCS products and licenses for aviation operations.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points from lengthy filings, helping users quickly identify information on topics such as revenue drivers, risk factors, and logistics investments. Real-time updates from EDGAR, along with easy access to insider transaction reports on Form 4 and proxy materials on executive and governance matters, make this page a focused resource for analyzing TMDX’s regulatory record and corporate reporting over time.
TransMedics Group (TMDX) Form 4: A director exercised 4,142 stock options at $0.70 on 10/29/2025 and sold 4,142 common shares at $130.45 the same day under a Rule 10b5-1 trading plan entered on November 6, 2024. After these transactions, the director directly owned 2,866 shares. The option was fully vested and carried a stated expiration of 02/16/2026, with zero derivative securities remaining afterward.
TransMedics Group (TMDX) reported strong third-quarter results. Total revenue rose to $143.8 million, up from $108.8 million a year ago, with net income of $24.3 million versus $4.2 million last year. Gross profit reached $84.6 million, reflecting higher product and service activity across the Organ Care System (OCS) platform.
Growth was concentrated in the United States, where OCS transplant revenue totaled $139.0 million, led by liver at $107.9 million and heart at $27.4 million. Diluted EPS was $0.66 (basic $0.71). Year‑to‑date, revenue was $444.7 million with $84.9 million of net income and $158.3 million in cash from operations.
The balance sheet strengthened with $466.2 million in cash and $355.2 million in stockholders’ equity. The company reported $452.1 million net carrying value of its 1.50% convertible senior notes due 2028 and $54.6 million in long‑term bank debt. As of October 17, 2025, 34,174,325 common shares were outstanding.
TransMedics Group, Inc. (TMDX) furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company specifies the information is being furnished, not filed, meaning it is not subject to Section 18 liability and will only be incorporated into other filings if expressly referenced. The common stock trades on the Nasdaq Global Market under the symbol TMDX.
TransMedics Group, Inc. filed a Form 8-K disclosing a material event: the company considers certain Acquisitions to be a series of related transactions to acquire a fleet of aircraft for use in its National OCS Program. The filing identifies this as a material event and is signed by Gerardo Hernandez, Chief Financial Officer and Treasurer on October 6, 2025. The notice states the purpose of the aircraft is to support the company’s National OCS Program but provides no financial terms, sources of financing, timelines, or specific aircraft counts in the disclosed text.
TransMedics Group’s President and CEO Waleed H. Hassanein, through the Waleed H. Hassanein Revocable Trust, reported open‑market purchases of the company’s common stock. On August 6, 2025, the trust bought 8,400 shares at a weighted average price of $118.68.
On August 7, 2025, the trust made additional open‑market purchases of 6,617 shares at a weighted average price of $116.08 and 1,858 shares at a weighted average price of $116.85. After these transactions, the trust indirectly held 486,234 shares, and Hassanein directly held 121,424 shares.
Form 4 summary: Reporting person Edward M. Basile (Director) filed a Form 4 for TransMedics Group, Inc. (TMDX) reporting transactions dated 08/04/2025.
Key reported items
- Non-derivative rows list 4,143 shares associated with a transaction code M and a quoted price of $0.70.
- A contemporaneous non-derivative row lists 4,143 shares with transaction code S and a price of $125.51.
- Post-transaction beneficial ownership figures shown: 7,009 shares and 2,866 shares (as reported).
- Derivative disclosure: a stock option with conversion/exercise price $0.70, underlying 4,143 common shares, exercisable 02/16/2026, and 4,142 derivative securities reported as beneficially owned following the transaction.
- Explanations state the option is fully vested and was adjusted on a 3.5-for-1 basis in connection with a pre-IPO conversion.
Filing: Signed by Attorney-in-Fact Gerardo Hernandez on 08/05/2025.